Eagle Point Credit Company Inc. Schedules Release of First Quarter 2026 Financial Results on Tuesday, May 19, 2026

Eagle Point Credit Company Inc. announced it will release its financial results for the quarter ended March 31, 2026, on Tuesday, May 19, 2026. The company will also host a conference call on the same day at 10:00 a.m. Eastern Time to discuss the results, with CEO Thomas P. Majewski and CFO Kenneth P. Onorio leading the call. Investors can access the call via phone or webcast, with replays available afterward.

Original reporting
Published May 5, 2026, 10:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 5, 2026, 11:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ECC
Neutral
medium confidence
Mentioned
$ECC
Relevance
6/10
AlphAI data visualization · based on The National Law Review
Decision brief

The 30-second read

$ECCNeutralMed
01

Why it matters

The scheduled release is likely to cause short-term volatility; positive results could boost the stock, while negative results might lead to declines.

02

Market read

The earnings release is a significant event for ECC investors and traders, with potential to influence stock price and trading volume.

03

What to watch

Broader credit market conditions and interest rate trends could overshadow company-specific earnings impacts.

Relevance 6/10Timing: High, as the earnings release is scheduled for May 19, 2026.

Background

Eagle Point Credit Company Inc. is a closed-end fund investing primarily in credit-oriented assets. Earnings reports are key events that can influence its stock price and investor sentiment.

Company-level read

Ticker impact

$ECCNeutralMedium confidence
Context

The news pertains to Eagle Point Credit Company Inc., which is directly relevant to its stock ticker ECC.

Expected impact

Potential moderate increase or decrease in stock price post-earnings, depending on results versus expectations.

Evidence & confidence

Earnings reports typically cause volatility; however, since the news is scheduled and no prior guidance or analyst expectations are provided, the impact remains uncertain.

Market effects

The earnings release may influence investor sentiment in the credit and finance sectors, especially for closed-end funds.

Limited, as the news pertains to a US-based company with no immediate regional implications.

Negligible, given the company's specific market focus.

Counterpoint

Earnings results may be in line with expectations, leading to minimal price movement, making the event less actionable.

Key entities

  • Eagle Point Credit Company Inc.

    A credit-focused closed-end fund.

  • Thomas P. Majewski

    CEO of Eagle Point Credit Company Inc.

  • Kenneth P. Onorio

    CFO of Eagle Point Credit Company Inc.

Related articles

$ECCMed

Eagle Point Q3 2026 slides: private credit shift drives diversification

Eagle Point Credit Company (ECC) reported Q3 2026 results, with net investment income rising to $0.31 per share. The company is shifting toward private credit, now 38% of its portfolio. NAV declined 8% to $4.17 per share. ECC trades at $2.295, up 7.75% from the previous close. Management declared monthly distributions of $0.06 per share for early 2027. The company's AUM stands at $14 billion.

$BRFHMed

Barfresh Manufacturing Recovery Drives Margins – Quarterly Update Report

Barfresh Manufacturing (BRFH) reported 3Q26 revenue of $5.8M, up 37% y/y, with gross margin rebounding to 20.9% from negative 3.2% q/q. Core margins reached 34%, and adjusted EBITDA neared breakeven. The company added 50 Ohio school districts and reactivated a major Florida district. 2026 revenue guidance was revised to $20M-$22M, with Defiance facility commissioning targeted for early to mid-2027. BRFH trades at a 75% discount to peers, offering potential rerating as growth accelerates.

$PYXSHighAI 9/10

Pyxis reports updated phase 1 data for cancer drug candidate

Pyxis Oncology (PYXS) reported updated Phase 1 data for micvotabart pelidotin, showing a 39% response rate in 33 patients with recurrent/metastatic head and neck cancer. The study reported a median progression-free survival of 6.7 months and a 94% disease control rate. Pyxis plans to initiate a Phase 3 trial in mid-2027 and expects to release more mature overall survival data in the first half of 2027.

$PYXSMedAI 8/10

Pyxis Oncology (PYXS) Reports 39% Confirmed MICVO Response Rate

Pyxis Oncology (PYXS) reported updated Phase 1 data for MICVO, showing a 39% confirmed response rate, 9.2-month median response duration, and 6.7-month median PFS in 33 patients. The company plans to start a global Phase 3 trial in mid-2027. The data is not yet confirmatory, and further results are expected in early 2027.